Literature DB >> 20556588

Effects of combined siRNA-TR and -TERT on telomerase activity and growth of bladder transitional cell cancer BIU-87 cells.

Wen Cheng1, Zhifeng Wei, Jianping Gao, Zhengyu Zhang, Jingping Ge, Kangzhen Jing, Feng Xu, Peng Xie.   

Abstract

The effects of combined RNA interference (RNAi) of human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) genes on telomerase activity in a bladder cancer cell line (BIU-87 cells) were investigated by using gene chip technology in vitro with an attempt to evaluate the role of RNAi in the gene therapy of bladder transitional cell cancer (BTCC). Three TR-specific double-stranded small interfering RNAs (siRNAs) and three TERT-specific double-stranded siRNAs were designed to target different regions of TR and TERT mRNA. The phTR-siRNA, phTERT-siRNA, and the combination of both plasmids phTR+phTERT-siRNA were transfected into BIU-87 cells. The expression of hTR and hTERT mRNA was detected by quantitative fluorescent reverse transcription-polymerase chain reaction, and a telomeric repeat amplification protocol was applied to detect telomerase activity. Growth inhibition of BIU-87 cells was measured by MTT assay. Gene chip analysis was performed to evaluate the effects of the combined RNAi of hTR+hTERT genes on telomerase activity and growth of BIU-87 cells in vitro. The results showed that the expression of hTERT and hTR mRNA was inhibited by pRNAT-hTERT-III, pRNAT-hTR-III, and pRNAT-hTR-III+hTERT-III in BIU-87 cells. The inhibition efficiency of pRNAT-hTERT-III, pRNAT-hTR-III, pRNAT-hTERT-III+pRNAT-hTR-III was 67% for TERT mRNA, 41% for TR mRNA, 57% for TR mRNA and 70% for TERT mRNA in BIU-87 cells respectively. The growth of BIU-87 cells was inhibited and telomerase activity was considerably decreased, especially in the cells treated with combined RNAi-hTR and -hTERT. Gene chip analysis revealed that 21 genes were down-regulated (ATM, BAX, BCL2, BCL2L1, BIRC5, CD44, CTNNB1, E2F1, JUN, MCAM, MTA1, MYC, NFKB1, NFKBIA, NME4, PNN, PNN, SERPINE1, THBS1, TNFRSF1A, and UCC1). The results indicated that hTR-siRNA and hTERT-siRNA, especially their combination, siRNA hTR+hTERT, specifically and effectively suppressed the expression of both hTR and hTERT mRNA and telomerase activity. Molecular biological mechanism by which combined siRNA-TR and -TERT inhibited telomerase activity and growth of BIU-87 cells in vitro may involve the down-regulation of the 21 genes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556588     DOI: 10.1007/s11596-010-0363-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  26 in total

1.  shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity.

Authors:  Lin Zou; Penghui Zhang; Chunli Luo; Zhiguang Tu
Journal:  Cancer Chemother Pharmacol       Date:  2005-07-19       Impact factor: 3.333

Review 2.  Telomeres, telomerase, and immortality.

Authors:  M S Rhyu
Journal:  J Natl Cancer Inst       Date:  1995-06-21       Impact factor: 13.506

3.  Expression of the catalytic subunit associated with telomerase gene in human urinary bladder cancer.

Authors:  T Suzuki; Y Suzuki; T Fujioka
Journal:  J Urol       Date:  1999-12       Impact factor: 7.450

4.  Induction of apoptosis and inhibition of telomerase activity in human bone marrow and HL-60 p53 null cells treated with anti-cancer drugs.

Authors:  I Malerba; L Gribaldo; C Diodovich; M Carloni; R Meschini; G Bowe; A Collotta
Journal:  Toxicol In Vitro       Date:  2005-06       Impact factor: 3.500

5.  Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells.

Authors:  Y Koyanagi; D Kobayashi; T Yajima; K Asanuma; T Kimura; T Sato; T Kida; A Yagihashi; H Kameshima; N Watanabe
Journal:  Anticancer Res       Date:  2000 Mar-Apr       Impact factor: 2.480

6.  Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA.

Authors:  K Fujimoto; M Takahashi
Journal:  Biochem Biophys Res Commun       Date:  1997-12-29       Impact factor: 3.575

7.  Telomerase activity as a potential marker in preneoplastic bladder lesions.

Authors:  F Lancelin; M Anidjar; J M Villette; A Soliman; P Teillac; A Le Duc; J Fiet; O Cussenot
Journal:  BJU Int       Date:  2000-03       Impact factor: 5.588

8.  Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells.

Authors:  Xiangbai Wu; Yongzhi Deng; Guobin Wang; Kaixiong Tao
Journal:  J Surg Res       Date:  2006-12-12       Impact factor: 2.192

9.  Short telomeres and ataxia-telangiectasia mutated deficiency cooperatively increase telomere dysfunction and suppress tumorigenesis.

Authors:  Ling Qi; Margaret A Strong; Baktiar O Karim; Mary Armanios; David L Huso; Carol W Greider
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

10.  E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.

Authors:  Martin Oeggerli; Sanja Tomovska; Peter Schraml; Daniele Calvano-Forte; Salome Schafroth; Ronald Simon; Thomas Gasser; Michael J Mihatsch; Guido Sauter
Journal:  Oncogene       Date:  2004-07-22       Impact factor: 9.867

View more
  2 in total

1.  Targeting Human Telomerase Reverse Transcriptase by a Simple siRNA Expression Cassette in HepG2 Cells.

Authors:  Hui Xu; Xia Gong; Hui Hui Zhang; Qin Zhang; Dandan Zhao; Jian Xiong Peng
Journal:  Hepat Mon       Date:  2015-03-31       Impact factor: 0.660

Review 2.  Telomere Gene Therapy: Polarizing Therapeutic Goals for Treatment of Various Diseases.

Authors:  JinWoo Hong; Chae-Ok Yun
Journal:  Cells       Date:  2019-04-28       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.